Formulation and Specifications: Tablets: 200mg
Indications: Treatment of inoperable or distant metastatic hepatocellular carcinoma.
Key points for rational drug use:
1. The most common adverse reactions during drug administration are diarrhea, fatigue, hair loss, infection, skin reactions on hands and feet, and rash.
2. The recommended dose is 0.4g/dose twice daily on an empty stomach or with a low-fat or medium-fat diet, and must be swallowed whole. Management of suspected adverse reactions includes suspension or reduction of dosage. If a dose reduction is required, the dose of sorafenib is reduced to 0.4g/dose once daily, orally.
3. Caution is required when combining with drugs that are metabolized/cleared via the UGT1A1 pathway (e.g., irinotecan, docetaxel). INR values should be tested regularly when combined with warfarin.
There is a lack of data from randomized controlled clinical studies comparing sorafenib with interventional therapies such as hepatic artery embolization chemotherapy (TACE) in patients with advanced hepatocellular carcinoma, so it is not clear whether this product is superior to interventional therapies or whether sorafenib is beneficial in patients who have received prior interventional therapy.
5. The TACTICS study (NCT01217034) confirmed a better benefit in the first TACE in combination with sorafenib than in the sorafenib group.